ライフサイエンスコーパス: randomization

1 identification of instruments for Mendelian randomization).

2 rflow decline-free survival at 2 years after randomization.

3 who had at least 1 outcome assessment after randomization.

4 as predictors of QoL benefits 3 months after randomization.

5 traits, such as pulse rate, using mendelian randomization.

6 hypoglycemia or diabetic ketoacidosis after randomization.

7 We performed a bi-directional Mendelian randomization.

8 year or failed cardioversion) AF patterns at randomization.

9 was ongoing pregnancy within 6 months after randomization.

10 eatly reduces the bias linked to the lack of randomization.

11 D) and myocardial infarction using mendelian randomization.

12 55 to 69 (ERSPC) or 55 to 74 (PLCO) years at randomization.

13 tion of abdominal imaging within 6 months of randomization.

14 005 McDonald criteria) within 6 months after randomization.

15 nal-replacement therapy within 30 days after randomization.

16 Nine participants completed randomization.

17 usted for level of encephalopathy and age at randomization.

18 ean age 55.3 years, 41.9% females) underwent randomization.

19 and myocardial infarction within 180 days of randomization.

20 and relapse in the first 16-week phase after randomization.

21 fatal ischemic stroke, or early death after randomization.

22 t of EF a mean (SD) of 13.5 (6) months after randomization.

23 ith indirect trial evidence while preserving randomization.

24 at baseline and approximately 6 months post-randomization.

25 , with measures at baseline and 1 year after randomization.

26 .1% albumin in saline on days 1 and 22 after randomization.

27 the trial was event-free survival (EFS) from randomization.

28 ith a focus on patients with a stroke before randomization.

29 h recurrent HE on SOC was conducted with 1:1 randomization.

30 A total of 501 patients underwent randomization.

31 by 10-year age group based on age at time of randomization.

32 through the intervention); this could mimic randomization.

33 They were followed for up to 2 years after randomization.

34 ticagrelor were similar early and late after randomization.

35 transplantation among patients who underwent randomization.

36 e between the diagnosis of heart failure and randomization.

37 n [reference]) at 12, 20, and 28 hours after randomization.

38 entilator-free hours in the 7 days following randomization.

39 EI-VFQ-25 composite score over 3 years after randomization.

40 of futility after 329 patients had undergone randomization.

41 23 (5.7%) had hen's egg-specific IgE before randomization.

42 Of the eligible patients, 1312 underwent randomization.

43 cancer or death assessed at 4.5 years after randomization.

44 A total of 437 patients underwent randomization.

45 Here we assess outcomes up to 4 years post-randomization.

46 arization, or stent thrombosis at 48 h after randomization.

47 wn and unknown prognostic factors offered by randomization.

48 ents per group); 59 patients did not undergo randomization.

49 growth across groups through four years post-randomization.

50 Randomization (1:1) to receive or not receive ACE inhibi

51 Of the 150 patients who underwent randomization, 1 patient died during the 5-year follow-u

52 Of the 1050 patients who underwent randomization, 1046 were included in the modified intent

53 Of 1634 fetuses that underwent randomization, 1566 were born alive before 30 weeks of g

54 longer mean duration of macular edema before randomization (18 months vs. 1 month for those without p

55 provided a fasting serum sample before study randomization (1985-1988).

56 Randomization 2:1 to arginine deprivation (ADI-PEG20, 36

57 d pregabalin and 101 received placebo; after randomization, 2 patients in the pregabalin group were d

58 had overt distant metastases at the time of randomization; 2 withdrew consent).

59 After enrollment and randomization, 31 volunteers received product, underwent

60 A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab g

61 Death at 21 months after randomization (33 months after coronary stenting).

62 A total of 717 patients underwent randomization; 360 were assigned to the midostaurin grou

63 City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits.

64 After randomization, 478 individuals (4.1%) had 502 ischemic e

65 Of the 510 patients who underwent randomization, 509 received tezacaftor-ivacaftor or plac

66 Of the 103 patients undergoing randomization (60 men [58.3%] and 43 women [41.7%]), 97

67 tal, 13316 male physicians (mean [SD] age at randomization, 64.0 [9.0] years in those receiving the a

68 Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascul

69 Of the 90 patients who underwent randomization, 79 completed the trial.

70 A total of 882 patients underwent randomization, 849 of whom received levosimendan or plac

71 003 participants were enrolled and underwent randomization; 8855 (98.4%) received a trial vaccine and

72 We assessed post-randomization AF events diagnosed via hospitalizations f

73 The median follow-up from randomization after transplantation was 50.2 months (ran

74 Bidirectional Mendelian randomization among up to 4,513 individuals of European

75 Mendelian randomization analyses are consistent with a causal effe

76 Mendelian randomization analyses evaluating the association betwee

77 ese findings were not supported by Mendelian randomization analyses for most metabolites.

78 for WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective studies supplem

79 Mendelian randomization analyses in current smokers showed a sligh

80 Additional integrative Mendelian randomization analyses of gene expression and DNA methyl

81 Mendelian randomization analyses suggest causal inverse associatio

82 lood gene expression and conducted Mendelian randomization analyses to investigate the functional and

83 We carried out two-sample Mendelian randomization analyses using the inverse-variance weight

84 Mendelian randomization analyses were performed using single nucle

85 Mendelian randomization analyses were then performed using 655 ind

86 Mendelian randomization analysis showed significant positive assoc

87 Additionally, the Mendelian randomization analysis suggests a causal relationship be

88 diabetes, and CHD was tested in a mendelian randomization analysis that combined case-control and cr

89 ausal factor for VTE, we performed Mendelian randomization analysis using a genetic risk score instru

90 lysis and summary statistics-based Mendelian randomization analysis, although further replication is

91 In a Mendelian randomization analysis, genetically elevated body mass i

92 Using inverse-variance weighted Mendelian randomization analysis, we found support for an effect o

93 Network Mendelian randomization analysis-an approach using genetic variant

94 e estimator for eGFR (P<0.01) in a Mendelian randomization analysis.

95 s in five countries, 4994 patients underwent randomization and 4919 (98.5%) were included in the prim

96 oportional hazard analysis for death between randomization and 6 months was performed by intervention

97 surgery involving bone) within 2 years after randomization and a between-group absolute difference of

98 were assessed at different time points after randomization and according to the length of time betwee

99 to multiple sclerosis within 24 months after randomization and changes on magnetic resonance imaging

100 d on the first repeated EF measurement after randomization and compared all-cause mortality in 649 pa

101 ible, and specification of the delay between randomization and initiation of the intervention.

102 in eGFR (<5%, 5% to <20%, or >/=20%) between randomization and months 3 and 4 of the trial (time to a

103 rough a disordered network is accompanied by randomization and possible conversion into thermal light

104 Of 369 patients enrolled, 220 underwent randomization and started receiving benralizumab or plac

105 were associated with worse asthma control at randomization and subsequent increased risk of healthcar

106 of stroke) through at least 24 months after randomization and the 24-month incidence of new brain in

107 A total of 1500 adults underwent randomization and were followed for 12 months.

108 A total of 663 patients underwent randomization and were followed for a mean (+/-SD) of 5.

109 however, all current studies have a lack of randomization and/or a control group (sham).

110 mized patients, 2 withdrew immediately after randomization, and 1 duplicate patient was identified.

111 A total of 361 patients underwent randomization, and 328 were included in the primary effi

112 posed to sucralose at baseline and/or before randomization, and nearly half were exposed after assign

113 mes were collected by staff blinded to group randomization, and no participants withdrew because of a

114 tients, 5,481 (35.6%) had a history of AF at randomization, and of these, 1,645 (30.0%) had paroxysma

115 terization of risk factors, use of Mendelian randomization, and the key issues of study design and an

116 A total of 9340 patients underwent randomization, and the median follow-up of the patients

117 ucinations were more likely to relapse after randomization, and the presence of baseline hallucinatio

118 s to assess this hypothesis with a Mendelian randomization approach that uses genetic variants as ins

119 We used a two-step Mendelian randomization approach to assess whether DNA methylation

120 to derive causal estimates using a mendelian randomization approach.

121 broad range of tissues by using a Mendelian randomization approach.

122 Both replication and randomization are necessary.

123 umber of eligible patients necessary in each randomization arm was estimated to be 190, and an outcom

124 Under mendelian randomization assumptions, our findings suggest a protec

125 total of 142 eligible participants underwent randomization at 12 Canadian multiple sclerosis clinics;

126 A total of 198 patients underwent randomization at 60 sites.

127 A total of 1746 patients underwent randomization at 87 centers.

128 en with subclinical hypothyroidism underwent randomization at a mean of 16.7 weeks of gestation, and

129 elated to diseases, we developed a Mendelian randomization-based method combining 58 disease-related

130 essentially all of our analytic, numerical, randomization-based, and empirical examples.

131 Second, a double-blind randomization between doxycycline (200 mg/day, once dail

132 compared in terms of study design features (randomization, blinding, comparator, primary end point).

133 Randomization, blinding, sample size estimation, and con

134 In a subset of 1681 preclinical studies, randomization, blinding, sample size estimation, and inc

135 Methodological quality of studies including randomization, blinding, type of controls, clinical vs s

136 h after hospitalization up to 52 weeks after randomization, but this association was no longer signif

137 cantly better renal function at 1 year after randomization compared with patients remaining on CNI (m

138 tool has 11 items in the following domains: randomization, concealment, baseline differences, blindi

139 Four sets of sessions were conducted after randomization (days 1-3, 4-6, 8-10, and 11-13).

140 reased risk of CHD using a network Mendelian randomization design.

141 The first step Mendelian randomization estimated that maternal vitamin B12 had a

142 Here, we show that Mendelian randomization estimates of total and direct effects can

143 I (ELAIN) Trial from 90 days to 1 year after randomization for 230 (99.6%) patients.

144 The second step Mendelian randomization found weak evidence of a causal effect of

145 We applied the Mendelian randomization framework to evaluate the causal hypothesi

146 ored serum samples obtained 3-6 months after randomization from a total of 1232 white and black patie

147 A total of 1917 patients underwent randomization from November 2011 through January 2014.

148 In Mendelian randomization, genetic variants are used as unconfounded

149 ral anticoagulation (anticoagulation group) (randomization group 1).

150 ays to final referral diagnosis according to randomization group could be shown (7.2 vs. 7.6 d).

151 months of age; data collectors were blind to randomization group.

152 alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral

153 In the analysis of randomization groups 1 and 2, no stroke occurred among t

154 In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 18

155 alone was performed with combined data from randomization groups 1 and 3.

156 icated treatment or to antiplatelet therapy (randomization groups 2 and 3).

157 inomial regression models, we compared the 2 randomization groups.

158 s without AF, patients with paroxysmal AF at randomization had a higher risk of the primary composite

159 Among the 62 patients who underwent randomization, imatinib treatment reduced airway hyperre

160 A total of 872 women underwent randomization in Elaris EM-I and 817 in Elaris EM-II; of

161 Of the 500 patients who underwent randomization in the original trial, 2-year data for thi

162 0%]; mean [SD] age, 62 [11] years) underwent randomization in the trial.

163 We then conduct a 2-sample Mendelian randomization investigation to assess the causal roles o

164 Two-sample Mendelian randomization investigation using published data.

165 Mendelian randomization is the use of genetic variants as instrume

166 A computer-generated randomization list was used to allocate participants to

167 review provides an overview of the Mendelian randomization method, addresses assumptions and implicat

168 ults were obtained using different mendelian randomization methods and a more conservative set of ins

169 Egger regression and multivariable Mendelian randomization methods to control for this type of bias a

170 dence of MI was assessed over 3 months after randomization (months 12-15) and 3 months after study dr

171 At 28 days after randomization, mortality rate in the liberal group (prim

172 At 90 days after randomization, mortality rate in the liberal group was l

173 Mendelian randomization (MR) analyses were performed to examine th

174 ability analysis, and a two-sample Mendelian Randomization (MR) design to determine if elevated serum

175 r elevated serum IgE levels, using Mendelian randomization (MR) methodology to control bias owing to

176 Mendelian randomization (MR) provides less confounded results.

177 Mendelian randomization (MR) provides us the opportunity to invest

178 relation remains ambiguous.We used Mendelian randomization (MR) to infer the direction of causality b

179 tween RA and AD was assessed using Mendelian Randomization (MR), using summary data from the largest

180 lifestyle cannot be excluded, and Mendelian randomization needs to be examined in a larger sample.

181 ating comprehensive psychiatric assessments, randomization, objective documentation of compliance, an

182 of death from any cause within 1 year after randomization occurred in 5.0% of patients (166 of 3311)

183 large pore sizes, the complete orientational randomization of CO2 and structural fluctuations of the

184 ion requiring investigation is the potential randomization of cognate heavy (H) chain/light (L) chain

185 Simple 1:1 randomization of general practices in Germany was used.

186 e of similar magnitude as produced by paired randomization of neighborhoods.

187 decreases for increasing domain size due to randomization of Re-chains and formation of ReS2 subdoma

188 This nearly-immediate post-fission randomization of sister cell fates highlights the potent

189 uctuations that are responsible for complete randomization of the liquid structure.

190 A total of 209 patients underwent randomization, of whom 108 received pregabalin and 101 r

191 the POT-CAST trial, 1519 patients underwent randomization, of whom 1435 were included in the intenti

192 the POT-KAST trial, 1543 patients underwent randomization, of whom 1451 were included in the intenti

193 n-a-cone) followed by complete orientational randomization on a time scale of 900 +/- 20 ps, signific

194 After randomization, parasite prevalence increased over time i

195 Prior to randomization, patients indicated whether they preferred

196 Using block randomization, patients were randomized between oral stu

197 Methods We generated a randomization procedure that explicitly incorporates pre

198 In the randomization process, we used minimization to balance g

199 Prostate cancer incidence and survival from randomization; prostate cancer incidence in the United S

200 Four hours after randomization, pulmonary vascular mechanics was similar

201 In meta-analyses of 6 cRCTs with full randomization (rated as moderate quality overall), signi

202 or major bleeding during the 12 months after randomization, regardless of treatment duration.

203 Mendelian randomization requires large sample sizes, and power was

204 Block randomization resulted in comparable representation of k

205 t 1 skeletal-related event within 2 years of randomization (risk difference of -0.3% [1-sided 95% CI,

206 e randomized by using a hierarchical dynamic randomization scheme to continue their same dose of omal

207 ean ambulatory nighttime blood pressure from randomization showed a benefit for diastolic pressure at

208 Mendelian randomization showed no causal relation between H. pylor

209 The complete orientational randomization, slows from 136 ps in the bulk to 513 ps i

210 study, we used summary-data-based Mendelian randomization (SMR), a method developed to identify vari

211 he control group (relative risk adjusted for randomization strata, 1.13; 95% confidence interval [CI]

212 Using a 2.5:1 randomization strategy, 140 patients were randomized to

213 esign, with ERCC1 (8F1 antibody) status as a randomization stratification factor.

214 Mendelian randomization studies use genotypes as instrumental vari

215 on studies were used in a 2-sample Mendelian randomization study design.

216 We conducted a two-sample Mendelian randomization study to test the hypothesis that raised p

217 ex-specific manner, we performed a Mendelian randomization study using data from the Optimal well-bei

218 Two-sample mendelian randomization study using genetic variants associated wi

219 s of skin aging in a bidirectional Mendelian randomization study.

220 We used a two-sample Mendelian randomization study.

221 Our results using Mendelian randomization suggest that ALT reduces the risk of IHD,

222 The authors used 3 separate Mendelian randomization techniques to evaluate the associations of

223 Starting from randomization, the rate of event-free survival at 4 year

224 ebrovascular events at least 1 year prior to randomization; the Breslow-Day test was used to test for

225 xperimental error to the complete structural randomization time of BmimNTf2.

226 agnitude faster than the complete structural randomization time of neat BmimNTf2 liquid (870 +/- 20 p

227 ipants completed baseline assessments before randomization to 25 sessions of adaptive WMT or nonadapt

228 mprovement in KCCQ and FACIT-Pal scores from randomization to 6 months (KCCQ difference = 9.49 points

229 Time from randomization to a composite PDR-worsening outcome defin

230 At the time of randomization to active surveillance, a significant prop

231 From 15 days after randomization to age 9 months, early measles vaccination

232 Patients underwent a 1:1 randomization to an immersive preoperative VR experience

233 lly higher bleeding rates, regardless of the randomization to cangrelor or clopidogrel.

234 , indicative of ventricular fibrosis, before randomization to either CA or ongoing MRC.

235 Randomization to either daily oral flexible dose bupreno

236 Compared with chlorthalidone, randomization to either lisinopril (hazard ratio, 1.04;

237 We sought to determine whether randomization to lisinopril reduces incident AF or atria

238 table with both everolimus (mean change from randomization to month 12, -0.24 m/s; month 24, -0.03 m/

239 In contrast, a trial with sequential randomization to more intensive therapy achieved greater

240 Randomization to novel oral anticoagulants was associate

241 Randomization to receive 7.5 mg/d of oral insulin (n = 2

242 ed via central computerized double-blind 1:1 randomization to receive either a single loading dose of

243 ts and 72 children or adolescents) underwent randomization to receive either enhanced prophylaxis (90

244 Patients were allocated by block randomization to receive either percutaneous drainage of

245 They underwent simultaneous randomization to receive enhanced antimicrobial prophyla

246 Disease-free survival, defined as time from randomization to recurrence, second primary cancer, or d

247 Randomization to switching or not switching drugs would

248 Successful implantation after randomization to TAVR vs SAVR (PARTNER 1A; TAVR, n = 321

249 Randomization to the observation group, older age, thinn

250 Randomization to UC + PAL did not affect rehospitalizati

251 Cumulative BPAR rates from second randomization to year 10 for belatacept 4-weekly, belata

252 psy-proven acute rejection (BPAR) from first randomization to year 10 were 22.8%, 37.0%, and 25.8% fo

253 serum phosphate concentration from baseline (randomization) to end of treatment.

254 Then randomization took place, and the Pain Resource Nurse pr

255 al designs but can be detected in sequential randomization trial designs.

256 th; siblings were randomized together as one randomization unit.

257 Mendelian randomization uses genetic variants as markers of exposu

258 In conclusion, multivariable Mendelian randomization using summarized genetic data provides a r

259 erformed two-sample bi-directional Mendelian randomization using summary level genomewide association

260 e regression in </=5909 adults and Mendelian randomization (using cis-acting genetic variants in the

261 ual acuity (VA) letter score (VALS) from the randomization visit to the 6-month follow-up visit, base

262 tiation was 7.2 kg (SD, 3.1); mean weight at randomization was 103.6 kg (SD, 20.4).

263 to multiple sclerosis within 6 months after randomization was 18.5 percentage points (95% CI, 3.7 to

264 e incidence of sudden death at 90 days after randomization was 2.4% in the earliest trial and 1.0% in

265 of months from diagnosis of macular edema to randomization was 6 (range, 0-104 months).

266 to multiple sclerosis within 6 months after randomization was 61.0% in the placebo group and 33.4% i

267 To circumvent confounding, Mendelian randomization was applied in a subsample via the lactase

268 Randomization was balanced for age, sex, disease duratio

269 The outcome of the randomization was concealed from the patient and perinea

270 Randomization was done centrally.

271 Unrestricted computer-generated randomization was implemented by surgical nurses.

272 External, stratified randomization was performed according to age, sex, and p

273 Randomization was reported in 21.8%, blinding in 32.7%,

274 n change in left ventricular mass index from randomization was similar with everolimus versus CNI (mo

275 Randomization was stratified according to presence or ab

276 Randomization was stratified according to programmed dea

277 Randomization was stratified according to subtype of FLT

278 Randomization was stratified by gestational age groups.

279 Randomization was stratified by intact vs rupture of mem

280 Randomization was stratified by metformin use.

281 Replacement randomization was used to assign 362 healthy participant

282 Randomization was used to determine group assignment and

283 analysis with genetic instruments (Mendelian randomization) was used in an extensively genotyped case

284 Using 2-step epigenetic Mendelian randomization, we investigated the role of DNA methylati

285 Using two-sample Mendelian randomization, we obtained unconfounded estimates of the

286 Through simple randomizations, we show that the US academic system is g

287 tients who had experienced a stroke prior to randomization were at a higher risk of recurrence and de

288 ire (NEI-VFQ-25) for the first 3 years after randomization were evaluated semiannually.

289 on, estimated glomerular filtration rates at randomization were higher in TAC-C over EVR + rTAC (76.4

290 nary syndrome (between 15 and 90 days before randomization) were eligible for the trial.

291 trumental variable methods such as Mendelian randomization, which may be applied to evaluate causalit

292 sis was established or until 24 months after randomization, whichever came first.

293 s will undergo a preoperative ultrasound and randomization will be stratified for pre-existing gallst

294 DIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 pa

295 ntegrates genetic fine mapping and Mendelian randomization with epigenome-wide association studies to

296 xty-eight eyes treated with ranibizumab from randomization with gradable DRSS on baseline fundus phot

297 We performed a Mendelian randomization with instrumental variable analysis to est

298 A total of 136 participants underwent randomization, with 68 participants assigned to receive

299 A total of 245 patients underwent randomization, with 91 being assigned to escitalopram, 9

300 te orientation, altered spacing and discrete randomization within the binding elements.